rps6ka6 Antibody

What is the RPS6KA6 gene and its protein product?

RPS6KA6 encodes the p90 ribosomal S6 kinase-4 (RSK4), which belongs to the RSK family of serine/threonine kinases. The gene has multiple transcription initiation sites and alternative splice variants, resulting in mRNA variants that encompass four possible start codons . The wild-type RSK4 protein is approximately 90-kD, but several smaller isoforms at or below 72-kD have been observed in various cell lines . These smaller isoforms often appear as duplets or triplets on immunoblots, and their expression levels vary significantly depending on cell type and culture conditions . RSK4 is involved in cell proliferation, survival, and potentially tumor development, with interactions with important cell cycle regulators like cyclin D1 and c-Myc .

What are the common applications for RPS6KA6 antibodies?

RPS6KA6 antibodies are utilized across multiple experimental platforms. The most common applications include:

• Western Blotting (WB): For detecting RSK4 protein and its various isoforms in cell and tissue lysates .

• Immunohistochemistry (IHC): For examining RSK4 expression patterns in tissue sections, including paraffin-embedded samples .

• Immunofluorescence (IF): For visualizing subcellular localization of RSK4 in cultured cells .

• Enzyme-Linked Immunosorbent Assay (ELISA): For quantitative detection of RSK4 protein levels .

• Immunocytochemistry (ICC): For detecting RSK4 in cultured cells while preserving cellular morphology .

The selection of the appropriate application depends on your specific research questions and the nature of your experimental system.

How to select the appropriate RPS6KA6 antibody for my research?

Selecting the appropriate RPS6KA6 antibody requires consideration of several key factors:

• Target epitope: Antibodies targeting different regions (N-terminal, C-terminal, or specific amino acid sequences) may detect different isoforms or splice variants . For example, N-terminal antibodies (AA 15-45) have different specificity profiles than C-terminal antibodies .

• Species reactivity: Verify that the antibody recognizes RSK4 from your species of interest. Available antibodies may react with human, mouse, monkey, or other species .

• Application compatibility: Ensure the antibody is validated for your intended application (WB, IHC, IF, etc.) .

• Clonality: Both polyclonal and monoclonal antibodies are available for RSK4 detection, each with advantages for specific applications .

• Validation data: Review available characterization data, especially when using antibodies from resources like the Human Protein Atlas .

What are the typical host species and clonality options for RPS6KA6 antibodies?

RPS6KA6 antibodies are primarily developed in rabbits and mice:

• Rabbit-derived antibodies:

  • Polyclonal antibodies that recognize various epitopes on the RSK4 protein

  • May provide enhanced sensitivity for detecting low-abundance RSK4 variants

  • Common applications include WB, IHC, and IF

• Mouse-derived antibodies:

  • Both monoclonal (clones such as 8E8 and 3E2) and polyclonal options are available

  • Monoclonal antibodies offer high specificity for particular epitopes

  • Useful for applications requiring high reproducibility

The choice between rabbit and mouse antibodies may depend on compatibility with secondary detection systems and experimental design requirements.

How do I address potential cross-reactivity issues with RPS6KA6 antibodies?

Cross-reactivity is a significant concern when working with RSK4 antibodies due to sequence homology with other RSK family members. To address this issue:

• Epitope selection: Choose antibodies generated against unique regions of RSK4. C-terminal regions tend to have greater sequence divergence from other RSK family members .

• Validation approaches:

  • Perform pre-absorption tests with the immunizing peptide

  • Compare detection patterns using multiple antibodies targeting different epitopes

  • Include positive controls (tissues or cells known to express RSK4) and negative controls (RSK4 knockdown or knockout samples)

• Specificity verification: Confirm that the antibody detects the expected molecular weight pattern for RSK4 (90-kD for wild-type and smaller isoforms at or below 72-kD) . Remember that RSK4 often appears as multiple isoforms that vary among cell types .

• Consider protein-protein interactions: RSK4 interactions with other proteins (such as cyclin D1 and c-Myc) may mask epitopes in certain contexts .

How can I detect different isoforms of RSK4 protein?

Detecting various RSK4 isoforms requires strategic experimental design:

• Antibody selection: Use antibodies targeting conserved regions present in all isoforms for comprehensive detection, or epitope-specific antibodies to distinguish between variants .

• Resolution optimization for Western blotting:

  • Use gradient gels (e.g., 4-12%) to effectively separate isoforms with similar molecular weights

  • Extend running time to improve separation of closely migrating isoforms

  • Consider using Phos-tag™ gels to separate phosphorylated from non-phosphorylated forms

• Two-dimensional electrophoresis: Combine isoelectric focusing with SDS-PAGE to separate isoforms based on both charge and size.

• Control experiments: Include recombinant protein standards representing known RSK4 isoforms.

• Alternative detection methods: Consider mass spectrometry for definitive identification of specific isoforms and their post-translational modifications.

Remember that RSK4 isoform patterns may vary significantly between different cell lines and experimental conditions .

What are the optimized protocols for using RPS6KA6 antibodies in various applications?

Based on the available information, here are optimized protocols for key applications:

• Immunohistochemistry:

  • Dilution range: 1:20-1:50 for paraffin-embedded sections

  • Antigen retrieval: Heat-induced epitope retrieval in citrate buffer (pH 6.0)

  • Detection system: HRP-conjugated secondary antibody with DAB substrate

  • Counterstain: Hematoxylin for nuclear visualization

• Immunofluorescence:

  • Concentration: 0.25-2 μg/mL

  • Fixation: 4% paraformaldehyde followed by permeabilization with 0.1% Triton X-100

  • Blocking: 5% normal serum from the species of secondary antibody

  • Nuclear counterstain: DAPI or Hoechst

• Western Blotting:

  • Sample preparation: Include phosphatase inhibitors to preserve phosphorylation status

  • Protein loading: 20-50 μg total protein per lane

  • Transfer: Wet transfer recommended for high molecular weight variants

  • Blocking: 5% non-fat dry milk or BSA in TBST

  • Primary antibody incubation: Overnight at 4°C with gentle rocking

How do experimental conditions affect RSK4 expression and antibody detection?

Research has shown that experimental conditions significantly impact RSK4 expression and detection:

• Cell culture conditions:

  • Serum starvation enhances cyclin D1-mediated inhibition of RSK4 expression

  • Cell density affects RSK4 expression levels

  • Growth in anchorage-dependent versus anchorage-independent conditions alters RSK4 expression patterns

• Chemical treatments:

  • Demethylation agent 5-azacytidine inhibits deletion of the penultimate exon of RSK4

  • Indolocarbazole-derived inhibitors of CDK4/6 induce deletion of the first 39 nucleotides from exon 21 of human RSK4

  • Treatment with specific growth factors may alter RSK4 phosphorylation status

• Cell type specificity:

  • RSK4 expression varies greatly among different cell lines

  • Tumor cells may express different isoform patterns compared to normal tissues

  • Tissue-specific expression patterns have been observed (e.g., high expression in liver and Caco-2 colon carcinoma cells)

• Genetic background:

  • Interactions with regulatory proteins like cyclin D1 and c-Myc influence RSK4 expression

  • Genetic modifications that affect these regulators may indirectly impact RSK4 detection

What controls should I include when using RPS6KA6 antibodies?

Rigorous controls are essential for reliable RSK4 antibody experiments:

• Positive controls:

  • Cell lines with confirmed RSK4 expression (consult literature for appropriate options)

  • Recombinant RSK4 protein (full-length or fragments matching your antibody's epitope)

  • Tissues known to express RSK4 (e.g., liver, breast cancer tissues)

• Negative controls:

  • RSK4 knockdown or knockout cell lines

  • Cell lines with naturally low RSK4 expression

  • Secondary antibody-only controls to assess background staining

  • Isotype controls to evaluate non-specific binding

• Validation controls:

  • Peptide competition assays using the immunizing peptide

  • Multiple antibodies targeting different epitopes to confirm specificity

  • Known RSK4 inducers or repressors to demonstrate dynamic regulation

• Technical controls:

  • Loading controls for Western blotting (e.g., β-actin, GAPDH)

  • Tissue/cell morphology controls in immunohistochemistry/immunocytochemistry

  • Cross-reactivity assessment with other RSK family proteins

How do I troubleshoot weak or non-specific signals in RPS6KA6 detection?

When encountering detection problems with RSK4 antibodies:

• Weak signal troubleshooting:

  • Increase antibody concentration or incubation time

  • Enhance signal amplification (e.g., using biotin-streptavidin systems)

  • Optimize protein extraction to preserve RSK4 integrity (use phosphatase and protease inhibitors)

  • Try different epitope-targeting antibodies, as accessibility may vary by sample type

  • Consider that RSK4 wild-type is often sparse in cancer cell lines while smaller isoforms predominate

• Non-specific signal troubleshooting:

  • Increase blocking stringency (longer times, higher concentrations)

  • Add non-specific binding blockers (e.g., normal serum, BSA)

  • Optimize washing steps (increased duration or number of washes)

  • Reduce antibody concentration

  • Test antibody specificity with peptide competition assays

• Sample-specific considerations:

  • Adjust fixation protocols for immunohistochemistry/immunofluorescence

  • Optimize antigen retrieval methods for formalin-fixed samples

  • Consider alternative protein extraction methods for difficult samples

How can I validate the specificity of my RPS6KA6 antibody?

Comprehensive validation ensures reliable results with RSK4 antibodies:

• Multi-method confirmation:

  • Compare results across different detection techniques (WB, IHC, IF)

  • Verify that molecular weight patterns match expected RSK4 isoforms

  • Confirm subcellular localization patterns align with known RSK4 distribution

• Genetic manipulation approaches:

  • Use RSK4 overexpression systems to confirm signal increase

  • Employ RNA interference (siRNA, shRNA) to demonstrate signal reduction

  • Utilize CRISPR/Cas9 knockout models as definitive negative controls

• Comparative antibody analysis:

  • Test multiple antibodies targeting different RSK4 epitopes

  • Compare monoclonal and polyclonal antibodies for consistent detection patterns

  • Validate across several known positive and negative cell lines/tissues

• Functional correlation:

  • Correlate RSK4 detection with known functional outcomes

  • Verify expected changes during treatments that alter RSK4 expression (e.g., 5-azacytidine treatment)

What sample preparation techniques optimize RSK4 detection?

Effective sample preparation is crucial for reliable RSK4 detection:

• Protein extraction for Western blotting:

  • Use RIPA buffer supplemented with both phosphatase and protease inhibitors

  • Perform extraction at 4°C to minimize protein degradation

  • Consider sonication to improve extraction of nuclear-associated RSK4

  • Centrifuge at high speed (>14,000 × g) to remove cellular debris

• Tissue preparation for immunohistochemistry:

  • Fix tissues in 10% neutral buffered formalin for 24-48 hours

  • Optimize antigen retrieval methods (heat-induced epitope retrieval in citrate buffer)

  • Consider thinner sections (3-4 μm) for better antibody penetration

  • Use positive control tissues with known RSK4 expression patterns

• Cell preparation for immunofluorescence/immunocytochemistry:

  • Optimize fixation (4% paraformaldehyde for 10-15 minutes)

  • Include a permeabilization step with 0.1-0.5% Triton X-100

  • Perform blocking at room temperature for at least 1 hour

  • Consider using glass coverslips coated with poly-L-lysine for better cell adhesion

• Storage considerations:

  • Store antibodies at -20°C as recommended by manufacturers

  • Aliquot antibodies to avoid freeze-thaw cycles

  • Prepare fresh working dilutions for each experiment

How is RSK4 expression related to cellular processes and disease states?

RSK4 exhibits complex relationships with cellular processes and disease states:

• Cell cycle regulation:

  • Cyclin D1 inhibits RSK4 expression, and this inhibition is enhanced by serum starvation

  • Conversely, RSK4 inhibits cyclin D1, suggesting a feedback regulatory mechanism

  • c-Myc interacts with RSK4 in regulating cyclin D1

• Cell growth and death:

  • RSK4's effects on cell growth and death are highly context-dependent

  • Different mRNA variants or protein isoforms produce varying effects

  • Growth conditions (anchorage-dependent vs. independent) influence RSK4's impact

• Cancer biology:

  • RSK4 protein has been detected in human breast cancer tissues and cell lines

  • RSK4 mRNA is highly expressed in human and rat livers and Caco-2 human colon carcinoma cells

  • Different isoforms may have distinct roles in cancer progression

• Response to environmental factors:

  • Aroclor 1254 (a mixture of polychlorinated biphenyls) can induce RSK4 expression in the kidneys of rats with streptozotocin-induced diabetes

  • This suggests potential roles in stress response and environmental adaptation

What considerations are important when studying RSK4 in different cell types?

When investigating RSK4 across various cell types, researchers should consider:

• Baseline expression variability:

  • RSK4 expression levels vary dramatically between cell types

  • The 90-kD wild-type RSK4 is often sparse in cancer cell lines while smaller isoforms predominate

  • Expression patterns in normal tissues may differ from those in cancer-derived cell lines

• Isoform distribution:

  • The profile of RSK4 isoforms differs significantly between cell types

  • Some variants (such as the penultimate exon deleted variant) appear mainly in cell lines but not in most normal tissues

  • Use antibodies that can detect the relevant isoforms for your cell type of interest

• Regulatory network differences:

  • Interaction partners (cyclin D1, c-Myc) may vary in expression and activity across cell types

  • Pathway activation states affect RSK4 function and expression

  • Tissue-specific transcription factors may differentially regulate RSK4 expression

• Experimental validation:

  • Always validate RSK4 detection in new cell types using multiple antibodies

  • Establish baseline expression patterns before experimental interventions

  • Consider cell type-specific optimizations for detection protocols

How do I interpret conflicting data on RSK4 expression patterns?

Conflicting results regarding RSK4 expression are common due to its complex biology:

• Antibody-related factors:

  • Different antibodies may recognize distinct epitopes and therefore detect different subsets of RSK4 isoforms

  • Compare the exact epitopes targeted by each antibody used in conflicting studies

  • Some researchers report easy detection of RSK4 in certain tissues while others struggle, potentially due to antibody differences

• Isoform complexity:

  • A single cDNA might express multiple proteins, complicating interpretation

  • Alternative splicing (e.g., penultimate exon, first 15 nucleotides of exon 22 in mouse, first 39 nucleotides of exon 21 in humans) produces numerous variants

  • These variants may have different expression patterns and functions

• Experimental conditions:

  • Growth conditions significantly affect RSK4 expression

  • Serum starvation, cell density, and passage number can all influence results

  • In vivo versus in vitro environments may yield different patterns

• Resolution strategies:

  • Use multiple detection methods (protein vs. mRNA analysis)

  • Compare results across multiple antibodies targeting different epitopes

  • Carefully document experimental conditions to facilitate comparison across studies

  • Consider context specificity as a biological reality rather than conflicting data

What experimental approaches can elucidate RSK4 function in cell signaling pathways?

To investigate RSK4's role in signaling pathways:

• Genetic manipulation techniques:

  • Overexpression of specific RSK4 variants to identify isoform-specific functions

  • CRISPR/Cas9 knockout or knockdown approaches

  • Domain-specific mutations to identify functional regions

  • Inducible expression systems to study temporal effects

• Protein interaction studies:

  • Co-immunoprecipitation to identify binding partners (e.g., cyclin D1, c-Myc)

  • Proximity ligation assays to confirm interactions in situ

  • Yeast two-hybrid or BioID approaches for unbiased interaction screening

  • Fluorescence resonance energy transfer (FRET) to study dynamic interactions

• Signaling pathway analysis:

  • Phosphoproteomic analysis to identify RSK4 substrates

  • Inhibitor studies to position RSK4 within known signaling cascades

  • Reporter assays to measure pathway activation downstream of RSK4

  • Kinase activity assays to assess RSK4 enzymatic function

• Contextual studies:

  • Compare RSK4 function under different growth conditions (2D vs. 3D, anchorage-dependent vs. independent)

  • Assess responses to specific stressors or growth factors

  • Evaluate RSK4 function in different cell cycle phases

  • Examine effects of epigenetic modifiers like 5-azacytidine on RSK4 function